69.8% at 3 years (95% CI 63.9-75.7%) (Figure 1 ). Gleason score 8 or above [18] . Our data confirmed these results. The ideal end point on which to make treatment decisions is survival and PSA-defined 274 failure may not accurately reflect the likehood of prostate cancer-specific death. 275 However, early PSA failure is established to be associated with an increased risk of 276 progression to metastatic disease and prostate cancer-specific death [21] . One limitation of our study is the bias due to the selection of men candidates for RP. 
